4 results
Approved WMOCompleted
The primary objective of this study is to evaluate efficacy and safety. Secondary objectives: PK, PK-PD.
Approved WMOCompleted
The objective is to study the effect of beta-agonist and beta-antagonist treatment on human bone remodeling.
Approved WMOCompleted
Primary: Efficacy of FF/GW642444 100/25 mcg once daily in comparison with that of FP/salmeterol 250/50 mcg twice daily during 24 weeks.Secundary: Safety and tolerability.
Approved WMOWill not start
This study will evaluate the effectiveness and safety of a 36-week refill regimen for the PDS with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per a treat-and-extend regimen (aflibercept…